<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680162</article-id><article-id pub-id-type="doi">10.3390/v16121942</article-id><article-id pub-id-type="publisher-id">viruses-16-01942</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant Recipients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>von der Schulenburg</surname><given-names>Philippa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-viruses-16-01942" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3111-621X</contrib-id><name><surname>Behrens</surname><given-names>Georg M. N.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-viruses-16-01942" ref-type="aff">2</xref><xref rid="af3-viruses-16-01942" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4603-7696</contrib-id><name><surname>Hoffmann</surname><given-names>Markus</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af4-viruses-16-01942" ref-type="aff">4</xref><xref rid="af5-viruses-16-01942" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Linke</surname><given-names>Alexandra</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-viruses-16-01942" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Nehlmeier</surname><given-names>Inga</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af4-viruses-16-01942" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Kempf</surname><given-names>Amy Madeleine</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af4-viruses-16-01942" ref-type="aff">4</xref><xref rid="af5-viruses-16-01942" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3001-2478</contrib-id><name><surname>Stankov</surname><given-names>Metodi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af2-viruses-16-01942" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>L&#x000fc;tgehetmann</surname><given-names>Marc</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af6-viruses-16-01942" ref-type="aff">6</xref><xref rid="af7-viruses-16-01942" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Jahnke-Triankowski</surname><given-names>Jacqueline</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af8-viruses-16-01942" ref-type="aff">8</xref><xref rid="af9-viruses-16-01942" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2836-9224</contrib-id><name><surname>Addo</surname><given-names>Marylyn M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-viruses-16-01942" ref-type="aff">1</xref><xref rid="af6-viruses-16-01942" ref-type="aff">6</xref><xref rid="af10-viruses-16-01942" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name><surname>Fischer</surname><given-names>Lutz</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af8-viruses-16-01942" ref-type="aff">8</xref><xref rid="af9-viruses-16-01942" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name><surname>Lohse</surname><given-names>Ansgar W.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-viruses-16-01942" ref-type="aff">1</xref><xref rid="af6-viruses-16-01942" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6086-9136</contrib-id><name><surname>P&#x000f6;hlmann</surname><given-names>Stefan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af4-viruses-16-01942" ref-type="aff">4</xref><xref rid="af5-viruses-16-01942" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5033-1938</contrib-id><name><surname>Schulze zur Wiesch</surname><given-names>Julian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-viruses-16-01942" ref-type="aff">1</xref><xref rid="af6-viruses-16-01942" ref-type="aff">6</xref><xref rid="c1-viruses-16-01942" ref-type="corresp">*</xref><xref rid="fn1-viruses-16-01942" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Sterneck</surname><given-names>Martina</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-viruses-16-01942" ref-type="aff">1</xref><xref rid="af9-viruses-16-01942" ref-type="aff">9</xref><xref rid="fn1-viruses-16-01942" ref-type="author-notes">&#x02020;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Ramos-Lopez</surname><given-names>Irene</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01942"><label>1</label>I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; <email>p.vonderschulenbur@gmail.com</email> (P.v.d.S.); <email>a.linke@uke.de</email> (A.L.); <email>m.addo@uke.de</email> (M.M.A.); <email>alohse@uke.de</email> (A.W.L.); <email>sterneck@uke.de</email> (M.S.)</aff><aff id="af2-viruses-16-01942"><label>2</label>Department of Rheumatology and Immunology, Hannover Medical School, 30625 Hannover, Germany; <email>behrens.georg@mh-hannover.de</email> (G.M.N.B.); <email>stankov.metodi@mh-hannover.de</email> (M.S.)</aff><aff id="af3-viruses-16-01942"><label>3</label>German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, 38124 Braunschweig, Germany</aff><aff id="af4-viruses-16-01942"><label>4</label>Infection Biology Unit, German Primate Centre-Leibniz Institute for Primate Research, 37077 G&#x000f6;ttingen, Germany; <email>mhoffmann@dpz.eu</email> (M.H.); <email>inehlmeier@dpz.eu</email> (I.N.); <email>akempf@dpz.eu</email> (A.M.K.); <email>spoehlmann@dpz.eu</email> (S.P.)</aff><aff id="af5-viruses-16-01942"><label>5</label>Faculty of Biology and Psychology, Georg-August-University G&#x000f6;ttingen, 37073 G&#x000f6;ttingen, Germany</aff><aff id="af6-viruses-16-01942"><label>6</label>German Center for Infection Research (DZIF), Partner Site Hamburg-L&#x000fc;beck-Borstel-Riems, 38124 Braunschweig, Germany; <email>mluetgehetmann@uke.de</email></aff><aff id="af7-viruses-16-01942"><label>7</label>Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany</aff><aff id="af8-viruses-16-01942"><label>8</label>Department of Visceral Transplantation, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; <email>j.jahnke-triankowski@uke.de</email> (J.J.-T.); <email>lfischer@uke.de</email> (L.F.)</aff><aff id="af9-viruses-16-01942"><label>9</label>University Transplant Center, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany</aff><aff id="af10-viruses-16-01942"><label>10</label>Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany</aff><author-notes><corresp id="c1-viruses-16-01942"><label>*</label>Correspondence: <email>julianszw@googlemail.com</email></corresp><fn id="fn1-viruses-16-01942"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>19</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1942</elocation-id><history><date date-type="received"><day>20</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>04</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background/Objectives: The efficacy of monovalent BNT162b2 Omicron XBB.1.5 booster vaccination in liver transplant recipients (LTRs) has yet to be described, particularly regarding the immune response to emerging variants like JN.1. Methods: This study evaluated humoral and cellular immune responses in 34 liver transplant recipients (LTRs) with varying SARS-CoV-2 immune histories before and after receiving a BNT162b2 Omicron XBB.1.5 booster vaccination. The assessment involved variant-specific serology, pseudovirus neutralization tests, and Interferon-&#x003b3; release assays. Results: Participants had a median of four prior vaccinations, with 91.2% having a history of infection. Post-vaccination, significant increases in both Wuhan anti-S and Omicron-specific IgG antibodies and improved neutralization of B.1, XBB.1.5, and JN.1 pseudovirus particles were observed. Also, T-cell responses significantly increased post-vaccination. However, 17.6% of LTRs had no neutralizing antibodies against XBB.1.5 and JN.1, while 100% of healthy controls did. Shortly after vaccination, 18% of patients developed mild COVID-19. These LTRs had particularly low immune responses at baseline. Conclusions: The monovalent XBB.1.5 booster improved overall SARS-CoV-2-specific immunity. However, some LTRs still showed low or undetectable immune responses, indicating that ongoing monitoring and further booster doses are necessary in this high-risk group.</p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>vaccination</kwd><kwd>COVID-19</kwd><kwd>liver transplantation</kwd><kwd>XBB.1.5</kwd><kwd>JN.1</kwd><kwd>immunosuppression</kwd><kwd>cellular immune response</kwd><kwd>humoral immune response</kwd></kwd-group><funding-group><award-group><funding-source>DAMP Stiftung</funding-source></award-group><award-group><funding-source>Deutsche Forschungsgesellschaft (DFG, German Research Foundation) CRC1328 project A12</funding-source></award-group><award-group><funding-source>CRC1648 project C4</funding-source></award-group><award-group><funding-source>DZIF</funding-source></award-group><award-group><funding-source>DZIFTTU</funding-source><award-id>01709</award-id></award-group><award-group><funding-source>DFG</funding-source><award-id>CRC1648 D03</award-id></award-group><award-group><funding-source>EU project UNDINE</funding-source><award-id>101057100</award-id></award-group><award-group><funding-source>Ministry of Science and Culture of Lower Saxony in Germany</funding-source><award-id>14-76403-184</award-id></award-group><award-group><funding-source>projects 7FF22, 6FF22, 10FF22</funding-source></award-group><award-group><funding-source>BMBF</funding-source><award-id>01KX2121</award-id></award-group><funding-statement>Julian Schulze zur Wiesch received research funding from the DAMP Stiftung, Deutsche Forschungsgesellschaft (DFG, German Research Foundation) CRC1328 project A12, the CRC1648 project C4, and DZIF; Marylyn Martina Addo reported funding from the DZIFTTU 01709 and the DFG CRC1648 D03; Stefan P&#x000f6;hlmann acknowledges funding by the EU project UNDINE (grant agreement number 101057100), the COVID-19-Research Network of the State of Lower Saxony (COFONI) through funding from the Ministry of Science and Culture of Lower Saxony in Germany (14-76403-184), projects 7FF22, 6FF22, 10FF22, and BMBF (COVIM 2.0, 01KX2121). No further funding was used for the reported research.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01942"><title>1. Introduction</title><p>Vaccination has played a crucial role in reducing severe COVID-19 cases, hospitalizations, and deaths worldwide [<xref rid="B1-viruses-16-01942" ref-type="bibr">1</xref>]. However, liver transplant recipients (LTRs) are still a vulnerable population and exhibit a significantly impaired immune response to SARS-CoV-2 vaccination [<xref rid="B2-viruses-16-01942" ref-type="bibr">2</xref>,<xref rid="B3-viruses-16-01942" ref-type="bibr">3</xref>,<xref rid="B4-viruses-16-01942" ref-type="bibr">4</xref>], achieving only partial immunity even after multiple booster doses [<xref rid="B5-viruses-16-01942" ref-type="bibr">5</xref>,<xref rid="B6-viruses-16-01942" ref-type="bibr">6</xref>,<xref rid="B7-viruses-16-01942" ref-type="bibr">7</xref>,<xref rid="B8-viruses-16-01942" ref-type="bibr">8</xref>,<xref rid="B9-viruses-16-01942" ref-type="bibr">9</xref>,<xref rid="B10-viruses-16-01942" ref-type="bibr">10</xref>]. With waning immunity and the emergence of new immune escape variants, the protection level from previous SARS-CoV-2 vaccinations and infections remains uncertain but crucial for this high-risk populations. Data indicate that monovalent XBB.1.5-adapted vaccines elicit a strong immune response in healthy individuals, effectively targeting XBB.1.5 [<xref rid="B11-viruses-16-01942" ref-type="bibr">11</xref>]. On the other hand, the immune protection achieved by previous infections and variant-adapted vaccinations against the currently dominant variants, such as JN.1, KP.2, KP.3, and XEC, remain uncertain [<xref rid="B11-viruses-16-01942" ref-type="bibr">11</xref>,<xref rid="B12-viruses-16-01942" ref-type="bibr">12</xref>,<xref rid="B13-viruses-16-01942" ref-type="bibr">13</xref>]. JN.1, a BA.2.86 subvariant, has rapidly become predominant and is highly immune-evasive [<xref rid="B12-viruses-16-01942" ref-type="bibr">12</xref>,<xref rid="B13-viruses-16-01942" ref-type="bibr">13</xref>]. KP.2 and KP.3 have descended from JN.1 and differ only by a few mutations in spike protein. XEC, a recombinant variant of KS.1.1 and KP.3.3, shows an enhanced humoral evasion and is foreseen to become a dominant subvariant [<xref rid="B14-viruses-16-01942" ref-type="bibr">14</xref>,<xref rid="B15-viruses-16-01942" ref-type="bibr">15</xref>]. For this winter, the European Medicines Agency (EMA) has recommended new vaccines targeting JN.1 [<xref rid="B16-viruses-16-01942" ref-type="bibr">16</xref>,<xref rid="B17-viruses-16-01942" ref-type="bibr">17</xref>]<bold>.</bold> Despite the importance of vaccination for high-risk LTRs, data on the impact of the XBB.1.5 vaccine on the immune response to the JN.1 variant are lacking. This small, prospective single-center study aimed to evaluate the immune response following a monovalent BNT162b2 XBB.1.5 vaccination in LTRs last winter, offering insights to improve future vaccination strategies for this vulnerable population.</p></sec><sec id="sec2-viruses-16-01942"><title>2. Materials and Methods</title><p>We prospectively analyzed 34 adult LTRs who received a 30 &#x000b5;g dose of BNT162b2 Omicron XBB.1.5 (Raxtozinameran, BioNtech, Mainz, Germany) booster vaccination at the University Medical Center Hamburg-Eppendorf between September 2023 and January 2024. The vaccination followed the recommendations of the Robert Koch Institute (RKI), and COVID-19 vaccines were supplied by the Ministry of Health in Germany at the time of the study. The patients were consecutively enrolled during routine visits to our outpatient liver transplant unit based on their consent to participate in the study, which involved the collection of additional blood samples. Data were collected from questionnaires, electronic medical records and blood samples were taken before and four to six weeks post-vaccination.</p><p>This study was approved by the local ethics committee of Hamburg, Germany (Reg. numbers PV7103 and PV7298).</p><sec id="sec2dot1-viruses-16-01942"><title>2.1. Assessment of the Humoral and Cellular Spike-Specific Immune Response</title><p>SARS-CoV-2 IgG was measured using quantitative Enzyme-linked Immunosorbent Assays (ELISAs) against the Wuhan Hu-1 (EI 2606-9601-10 G, EUROIMMUN, L&#x000fc;beck, Germany), anti-Omicron (EI 2606-9601-30 G, EUROIMMUN, L&#x000fc;beck, Germany), and Nucleocapsid protein (EI 2606-9601-2 G, EUROIMMUN, L&#x000fc;beck, Germany), as previously described [<xref rid="B11-viruses-16-01942" ref-type="bibr">11</xref>,<xref rid="B18-viruses-16-01942" ref-type="bibr">18</xref>].</p><p>T-cell response was measured by a Wuhan-Hu-1 Spike-specific interferon-Gamma Release Assay (IGRA, EUROIMMUN, L&#x000fc;beck, Germany) [<xref rid="B6-viruses-16-01942" ref-type="bibr">6</xref>,<xref rid="B7-viruses-16-01942" ref-type="bibr">7</xref>,<xref rid="B9-viruses-16-01942" ref-type="bibr">9</xref>,<xref rid="B18-viruses-16-01942" ref-type="bibr">18</xref>].</p></sec><sec id="sec2dot2-viruses-16-01942"><title>2.2. Production of Pseudovirus Particles (Pps) and Pseudovirus Neutralization Tests (pVNTs)</title><p>pVNTs were performed at the Infection Biology Unit of the German Primate Centre in G&#x000f6;ttingen according to a previously published protocol with slight modifications [<xref rid="B11-viruses-16-01942" ref-type="bibr">11</xref>,<xref rid="B19-viruses-16-01942" ref-type="bibr">19</xref>]. Briefly, neutralization efficiency was assessed based on the relative pseudovirus entry inhibition, with signals generated using pseudovirus particles incubated in the absence of plasma serving as reference (=0% inhibition). A non-linear regression model was applied to calculate the neutralizing titer 50 (NT50), representing the plasma dilution necessary for achieving half-maximal inhibition.</p></sec><sec id="sec2dot3-viruses-16-01942"><title>2.3. Statistical Analysis</title><p>Descriptive statistics were presented as median (range) for continuous variables or number (percentage) for categorical variables. Neutralization titers were transformed into geometric mean titers (GMTs). SPSS statistics version 27 (IBM Corp, Armonk, NY, USA) was used for statistical analysis, employing Pearson&#x02019;s chi-squared test, Fisher&#x02019;s exact test, Mann&#x02013;Whitney U Test, Wilcoxon signed-rank test, Kruskal&#x02013;Wallis test, or Spearman&#x02019;s rank correlation. Prism GraphPad 8.0.1 (Windows, Graph-Pad Software, San Diego, CA, USA) was used to create figures.</p></sec></sec><sec sec-type="results" id="sec3-viruses-16-01942"><title>3. Results</title><sec id="sec3dot1-viruses-16-01942"><title>3.1. Study Cohort and Patient Characteristics</title><p>Clinical and demographic details of the 34 LTRs included in this study are shown in <xref rid="viruses-16-01942-t001" ref-type="table">Table 1</xref>. Most LTRs (median age: 56 years) were long-term recipients with a median of 9.5 (range: 0&#x02013;28) years since transplantation. This real-world study cohort had a heterogeneous vaccination and infection status: the median number of prior vaccine doses was four (range: 2&#x02013;5), and 91.2% (31/34) of patients had a previous SARS-CoV-2 infection; only 8.8% (3/34) had no history or serological evidence of a prior infection. Most patients had exclusively received mRNA vaccines, while only a few (<italic toggle="yes">n</italic> = 5) had additionally received a viral vector vaccine. Notably, all patients had received at least two doses of mRNA vaccine in the past. Blood samples were analyzed before and within a median of 33.5 days (range: 22&#x02013;56) after vaccination. Of note, six patients developed confirmed COVID-19 with mild symptoms shortly after vaccination (median of 16 days after vaccination, range: 1&#x02013;34) (<xref rid="app1-viruses-16-01942" ref-type="app">Supplementary Table S1</xref>).</p></sec><sec id="sec3dot2-viruses-16-01942"><title>3.2. Humoral Immune Response Determined by ELISAs</title><p>We determined the Wuhan-Hu-1 anti-S and the anti-Omicron IgG titers before and after XBB.1.5 vaccination (<xref rid="viruses-16-01942-f001" ref-type="fig">Figure 1</xref>) in all LTRs (<italic toggle="yes">n</italic> = 34, <xref rid="viruses-16-01942-f001" ref-type="fig">Figure 1</xref>A,B), in LTRs who did not have a breakthrough infection shortly after vaccination (<italic toggle="yes">n</italic> = 28, <xref rid="viruses-16-01942-f001" ref-type="fig">Figure 1</xref>C,D), and in LTRs with breakthrough infection shortly after vaccination (<italic toggle="yes">n</italic> = 6, <xref rid="viruses-16-01942-f001" ref-type="fig">Figure 1</xref>E,F). A strong correlation (Spearman r = 0.98, <italic toggle="yes">p</italic> &#x0003c; 0.001, <xref rid="app1-viruses-16-01942" ref-type="app">Supplementary Figure S1A</xref>) was found between both assays. At baseline, 1/34 (2.9%) and 3/34 LTRs (8.8%) were negative for Wuhan anti-S and anti-Omicron IgG, respectively. At baseline, the median Wuhan anti-S and anti-Omicron IgG levels of all LTRs were 909.5 BAU/mL and 109.3 RU/mL (<xref rid="viruses-16-01942-f001" ref-type="fig">Figure 1</xref>A,B), respectively, which is slightly lower compared to our previously published cohort of 65 healthcare workers (HCWs) (mean: Wuhan anti-S IgG: 1422 BAU/mL, anti-Omicron IgG: 199 RU/mL) [<xref rid="B11-viruses-16-01942" ref-type="bibr">11</xref>]. Post-vaccination, all 28 LTRs without additional infection tested positive for Wuhan anti-S IgG and all but one for anti-Omicron IgG (<xref rid="viruses-16-01942-f001" ref-type="fig">Figure 1</xref>C,D). Also, a significant 3.8-fold change in Wuhan anti-S IgG titers (945 to 3595 BAU/mL; <italic toggle="yes">p</italic> &#x0003c; 0.0001) and a 5.1-fold change in anti-Omicron IgG levels (from 110 to 555.6 RU/mL; <italic toggle="yes">p</italic> &#x0003c; 0.0001) were seen in this group. In comparison, there was a slightly less pronounced increase in our previously published cohort of HCWs (2.9 and 3.6-fold change for Wuhan and Omicron anti-S IgG, respectively) [<xref rid="B11-viruses-16-01942" ref-type="bibr">11</xref>].</p><p>For the six LTRs with infections shortly after vaccination (<xref rid="viruses-16-01942-f001" ref-type="fig">Figure 1</xref>E,F), baseline titers were very low (613 BAU/mL and 74 RU/mL for Wuhan and Omicron anti-S, respectively). Still, after vaccination and infection, they showed a strong 6.1-fold and 8.0-fold increase in Wuhan and Omicron anti-S levels. This resulted in similar median titers (3735 vs. 3595 BAU/mL and 581 vs. 555.5 RU/mL for Wuhan anti-S and anti-Omicron IgG, respectively) compared to those in booster-vaccinated LTRs without breakthrough infection.</p><p>Notably, the three LTRs without any prior infection had significantly lower median IgG levels both before (131 vs. 978 BAU/mL; <italic toggle="yes">p</italic> = 0.014 and five vs. 111 RU/mL; <italic toggle="yes">p</italic> = 0.005 for Wuhan anti-S and anti-Omicron IgG, respectively) and after vaccination (226 vs. 3934 BAU/mL; <italic toggle="yes">p</italic> = 0.007 and 26 vs. 591 RU/mL; <italic toggle="yes">p</italic> = 0.009 for Wuhan anti-S and anti-Omicron IgG, respectively) compared to previously infected LTRs (<xref rid="app1-viruses-16-01942" ref-type="app">Supplementary Table S2, Supplementary Figure S2</xref>).</p></sec><sec id="sec3dot3-viruses-16-01942"><title>3.3. Neutralization of Pseudovirus Particles</title><p>Neutralization was analyzed using pseudovirus particles (pps) with SARS-CoV-2 spike proteins from the B.1, XBB.1.5, and JN.1 lineages. Baseline response rates (<italic toggle="yes">n</italic> = 34) were 85% for B.1 pps but only 53% and 44% for XBB.1.5 pps and JN.1 pps, respectively (<xref rid="viruses-16-01942-f002" ref-type="fig">Figure 2</xref>A). Also, XBB.1.5 pps and JN.1 pps were less efficiently neutralized than B.1 pps (GMTs for B1, XBB.1.5 and JN.1 of 71.7, 6.9, and 5.1, respectively). In comparison, 100% of HCWs responded to B.1 pps and 55% to XBB.1.5 pps with higher GMTs (1597 and 28, respectively) [<xref rid="B11-viruses-16-01942" ref-type="bibr">11</xref>]. After XBB.1.5 vaccination, response rates in LTRs without additional vaccination (<italic toggle="yes">n</italic> = 28) increased to 93%, 86%, and 86% for B.1 pps, XBB.1.5 pps, and JN.1 pps, respectively (<xref rid="viruses-16-01942-f002" ref-type="fig">Figure 2</xref>B). For B.1 pps, there was a 2.7-fold increase in GMTs (from 80 to 307.3, <italic toggle="yes">p</italic> &#x0003c; 0.001), while increases were higher for XBB.1.5 pps (9.1-fold, from 9.8 to 135.6, <italic toggle="yes">p</italic> &#x0003c; 0.001) and JN.1 pps (8.9-fold, from 7.2 to 93.2, <italic toggle="yes">p</italic> &#x0003c; 0.001). Notably, none of the three LTRs without prior SARS-CoV-2 infection responded to XBB.1.5 pps or JN.1 pps, and only one-third responded weakly to B.1 pps after vaccination (<xref rid="app1-viruses-16-01942" ref-type="app">Supplementary Figure S3</xref>). Altogether, there was a strong correlation between the neutralization of XBB.1.5 pps and JN.1 pps (Spearman r = 0.973, <italic toggle="yes">p</italic> &#x0003c; 0.001, <xref rid="app1-viruses-16-01942" ref-type="app">Supplementary Figure S1B</xref>).</p><p>Among the six LTRs with COVID-19 after vaccination (<xref rid="viruses-16-01942-f002" ref-type="fig">Figure 2</xref>C), baseline neutralization was 83% for B.1 pps but significantly lower, with only 16.7%, for XBB.1.5 pps and 0% for JN.1 pps compared to LTRs without infection after vaccination. Post-vaccination and infection, all six LTRs (100%) neutralized B.1 pps with a 3.0-fold change in GMTs (42.9 to 263.4). Neutralization capacities for XBB.1.5 pps and JN.1 pps increased, with a response rate of 67% for both pseudo particles and GMT fold changes of 60.5 and 97.6, respectively.</p><p>Altogether, post-vaccination 17.6% (6/34) of all LTRs showed no response to XBB.1.5 pps and JN.1 pps, while all HCWs did [<xref rid="B11-viruses-16-01942" ref-type="bibr">11</xref>]. Notably, non-responding LTRs had markedly lower antibody levels compared to responding LTRs, with highly significant differences observed for both Wuhan anti-S and anti-Omicron IgG (128.2 BAU/mL vs. 1161 BAU/mL, <italic toggle="yes">p</italic> = 0.001, and 6.7 AU/mL vs. 144 AU/mL, <italic toggle="yes">p</italic> = 0.001, respectively). Similarly, the lower rate of previous infections was also highly significant in non-responding LTRs (50% vs. 100%, <italic toggle="yes">p</italic> = 0.003; <xref rid="app1-viruses-16-01942" ref-type="app">Supplementary Table S3</xref>).</p></sec><sec id="sec3dot4-viruses-16-01942"><title>3.4. Spike-Specific T-Cell Response Measured by IGRA</title><p>Altogether, six LTRs were studied before and thirteen after XBB.1.5 booster vaccination (<xref rid="viruses-16-01942-f003" ref-type="fig">Figure 3</xref>). Before vaccination, two patients showed no T-cell response after spike-specific stimulation, while afterward, all LTRs showed a positive IFN-&#x003b3; release. The median IFN-&#x003b3; levels rose from 132.3 mlU/mL to 1210 mlU/mL (<italic toggle="yes">p</italic> = 0.046). One LTR without prior infection was assessed and showed a negative result before and a low positive result (&#x0003c;200 mlU/mL) after vaccination.</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-16-01942"><title>4. Discussion</title><p>Here, we investigated LTRs&#x02019; humoral and cellular immune responses following XBB.1.5 booster vaccination in the fall and early winter of 2023 to evaluate their potential protection against different SARS-CoV-2 variants, particularly the JN.1 variant.</p><p>Overall, in this real-world cohort of LTRs with a median of four prior vaccinations and a prior infection rate of 91.2%, the XBB.1.5 booster vaccination led to a strong increase in humoral and cellular immune response. In vitro neutralization rates showed increased response rates against all variant particles, including B.1, XBB.1.5, and JN.1. However, 17.6% of LTRs (6/34) still showed no neutralizing antibody response against XBB.1.5 pps and JN.1 pps after vaccination.</p><p>We used two ELISAs to determine spike-specific IgG antibodies against Wuhan and Omicron variants. Both assays showed a strong correlation and high favorable rates of detectable antibodies even at baseline in LTRs (Wuhan anti-S 97.1% and anti-Omicron IgG 91.2%), with median titers slightly lower than those in HCWs [<xref rid="B11-viruses-16-01942" ref-type="bibr">11</xref>]. This may suggest a similar baseline humoral immune response with LTRs having had more previous vaccine doses (median five vs. four) and more prior infections (91.2% vs. 81.5%).</p><p>However, for this in-depth analysis, we also conducted the neutralization assay, which demonstrated weaker humoral protection rates, with 14.8% showing no response to B.1 pps at baseline, compared to 100% of HCWs showing a response [<xref rid="B11-viruses-16-01942" ref-type="bibr">11</xref>]. Also, despite the high rate of prior SARS-CoV-2 infections, the baseline response rate to XBB.1.5 pps was only 52.9%, with a low GMT of 6.9, most likely due to a waning immune response [<xref rid="B5-viruses-16-01942" ref-type="bibr">5</xref>,<xref rid="B20-viruses-16-01942" ref-type="bibr">20</xref>]. The response rate to JN.1 pps was lower, with 44.1% and a GMT of 5.1. After vaccination, LTRs showed a reasonable response rate against both XBB.1.5 pps (82.4%) and JN.1 pps (82.4%), but with reduced neutralization capacities observed for JN.1 pps. Therefore, our findings and other studies [<xref rid="B16-viruses-16-01942" ref-type="bibr">16</xref>,<xref rid="B17-viruses-16-01942" ref-type="bibr">17</xref>,<xref rid="B21-viruses-16-01942" ref-type="bibr">21</xref>,<xref rid="B22-viruses-16-01942" ref-type="bibr">22</xref>] emphasize the need for vaccines targeting the JN.1 family, as recommended by regulatory agencies.</p><p>Six LTRs developed mild COVID-19 shortly post-vaccination, most likely from the Omicron variants EG.5 and BA.2.86 or its sublineage JN.1 [<xref rid="B23-viruses-16-01942" ref-type="bibr">23</xref>,<xref rid="B24-viruses-16-01942" ref-type="bibr">24</xref>]. At baseline, only one patient showed an immune response to XBB.1.5 pps and none to JN.1 pps. Also, the Wuhan anti-S and anti-Omicron antibody titers were all below a threshold of approximately 1200 BAU/mL and 180 AU/mL, respectively (<xref rid="app1-viruses-16-01942" ref-type="app">Supplementary Table S1</xref>), underscoring their susceptibility to COVID-19. In two patients, this lacking response persisted even after breakthrough-infection.</p><p>A definitive threshold for antibody titers that confer protection against COVID-19, whether against infection or severe illness, has not yet been established. Longitudinal studies with clinical endpoints are needed to determine such a threshold. However, the continuous emergence of new variants adds ongoing uncertainty regarding the effectiveness of immune protection against current strains [<xref rid="B7-viruses-16-01942" ref-type="bibr">7</xref>,<xref rid="B11-viruses-16-01942" ref-type="bibr">11</xref>,<xref rid="B15-viruses-16-01942" ref-type="bibr">15</xref>].</p><p>In LTRs, hybrid immunity, resulting from both previous infection and vaccination, has been shown to enhance immune responses [<xref rid="B10-viruses-16-01942" ref-type="bibr">10</xref>,<xref rid="B25-viruses-16-01942" ref-type="bibr">25</xref>]. Similarly, our findings underscore the importance of hybrid immunity, as the three previously uninfected LTRs exhibited particularly low antibody levels and showed no neutralization capacity against the XBB.1.5 and JN.1 variants, even after vaccination.</p><p>This is the first study to investigate LTRs&#x02019; immune response following a BNT162b2 Omicron XBB.1.5 booster vaccination. Our findings align with studies on other immunocompromised populations, which have demonstrated enhanced neutralizing responses to XBB.1.5 pps and JN.1 pps after booster vaccination [<xref rid="B21-viruses-16-01942" ref-type="bibr">21</xref>,<xref rid="B26-viruses-16-01942" ref-type="bibr">26</xref>]. However, Johnston et al. reported a decline in XBB.1.5 neutralization capacity within three months after receiving a bivalent booster in solid organ transplant recipients, which was restored by a second booster dose [<xref rid="B27-viruses-16-01942" ref-type="bibr">27</xref>].</p><p>In 2023, vaccination recommendations in Germany specifically called for the use of a monovalent variant-specific vaccine rather than a bivalent one. The monovalent booster demonstrated strong efficacy, as evidenced by the increased humoral and cellular immune responses and improved neutralization capacity in LTRs. Here, we demonstrate that the XBB.1.5-specific booster not only enhanced the humoral immune response against the wild-type Wuhan strain in LTRs but is particularly effective in enhancing the immune response against the XBB.1.5 and also the newer JN.1 variant (fold changes of 2.7, 9.1, and 8.9 for B.1, XBB.1.5 pps, and JN.1 pps, respectively). In agreement with our data, other studies have shown favorable outcomes of monovalent boosters. For instance, research comparing monovalent and bivalent mRNA vaccines found that the monovalent XBB.1.5 booster elicited significantly higher neutralizing antibody titers against the JN.1 variant compared to bivalent boosters targeting earlier variants such as BA.1 or BA.4&#x02013;5 [<xref rid="B28-viruses-16-01942" ref-type="bibr">28</xref>]. Initial studies in immunocompetent individuals concerning the monovalent vaccines based on the spike protein of JN.1 also show enhanced immune responses to JN.1, the Wuhan strain, and newly emerging variants [<xref rid="B29-viruses-16-01942" ref-type="bibr">29</xref>,<xref rid="B30-viruses-16-01942" ref-type="bibr">30</xref>].</p><p>Limitations of this study include the small, single-center cohort design, which may limit the generalizability of our findings to broader populations. Also, T-cell responses were only determined against the Wuhan variant. Furthermore, as a real-world study, the patients had heterogeneous vaccination and infection statuses at baseline, which might limit the comparability of the immune response findings. However, as vaccination strategies evolve, evaluating immune responses in homogeneous cohorts becomes almost impossible due to numerous influencing factors, such as prior vaccine types, varying numbers of doses, differing intervals since the last antigen exposure, diverse infection histories in terms of the number and variants of infections, and individual risk factors or immunosuppressive regimens. Studying a real-life cohort offers valuable insights into the full spectrum of immune responses, providing a comprehensive understanding of the collective immune status in this vulnerable population.</p></sec><sec sec-type="conclusions" id="sec5-viruses-16-01942"><title>5. Conclusions</title><p>In conclusion, our study revealed a lower baseline humoral immune protection in LTRs compared to HCW. The monovalent XBB.1.5 booster dose significantly enhanced immune responses with a stronger response to variants, including the newer JN.1 strain than to the wild type strain. However, approximately one in six LTRs still showed no response to XBB.1.5 and JN.1 variants after booster vaccination. Therefore, ongoing monitoring and variant-specific booster strategies are crucial to optimize future protection in this vulnerable group. Further studies with clinical endpoints are needed to determine the antibody and neutralization levels required for protection against infections.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors wish to thank all study participants and contributing departments of the University Medical Center Hamburg-Eppendorf for their active participation in this study.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-viruses-16-01942"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xlink:href="https://www.mdpi.com/article/10.3390/v16121942/s1">https://www.mdpi.com/article/10.3390/v16121942/s1</uri>, Supplementary Figure S1: (A) Correlation of Wuhan anti-S and anti-Omicron IgG, (B) Correlation of XBB.1.5 and JN.1 NT50; Supplementary Figure S2: (A) Wuhan-Hu-1 S-specific IgG, (B) Anti-S Omicron IgG; Supplementary Figure S3: Neutralisation in all LTR (n = 34); Supplementary Table S1: Comparison of LTRs with only vaccination and LTRs with COVID-19 following vaccination; Supplementary Table S2: Comparison of LTRs with and without prior SARS-CoV-2 infection; Supplementary Table S3: Comparison of LTRs with and without an immune response to the XBB.1.5pp in the neutralization assay following vaccination.</p><supplementary-material id="viruses-16-01942-s001" position="float" content-type="local-data"><media xlink:href="viruses-16-01942-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization: M.S. (Martina Sterneck), J.S.z.W., M.M.A., L.F., A.W.L. and G.M.N.B.; methodology: M.L., J.J.-T., M.H., S.P., A.M.K., I.N., M.S. (Metodi Stankov) and P.v.d.S.; validation: M.S. (Martina Sterneck) and J.S.z.W.; formal analysis: P.v.d.S., A.L., M.H., S.P. and M.S. (Metodi Stankov); investigation: P.v.d.S., M.H., S.P. and M.S. (Metodi Stankov); data curation: P.v.d.S., M.H., S.P. and M.S. (Metodi Stankov); writing&#x02014;original draft preparation: M.S. (Martina Sterneck), J.S.z.W., A.L. and P.v.d.S., writing&#x02014;review and editing: M.S. (Martina Sterneck), J.S.z.W., G.M.N.B., S.P., A.W.L., M.M.A. and L.F.; visualization: M.H., S.P., M.S. (Metodi Stankov) and P.v.d.S.; supervision: M.S. (Martina Sterneck) and J.S.z.W.; project administration: J.J.-T.; funding acquisition: M.S. (Martina Sterneck), J.S.z.W., M.M.A. and S.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was conducted in accordance with the Declaration of Helsinki and approved by the local Ethics Committee of Hamburg, Germany (Reg. Number PV7103 and PV7298) and the Paul Ehrlich Institute, the German Federal Institute for Vaccines and Biomedicines (Reg. number NIS508).</p></notes><notes><title>Informed Consent Statement</title><p>Written informed consent was obtained from all participants involved in this study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Individual participant data will not be shared.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>All authors declare that they have no known competing financial, professional, or personal conflicts that could have influenced the work reported in this paper. The funders had no role in the design of this study, in the collection, analyses, or interpretation of data, in the writing of this manuscript, or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01942"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akbulut</surname><given-names>S.</given-names></name>
<name><surname>Yagin</surname><given-names>F.H.</given-names></name>
<name><surname>Sahin</surname><given-names>T.T.</given-names></name>
<name><surname>Garzali</surname><given-names>I.U.</given-names></name>
<name><surname>Tuncer</surname><given-names>A.</given-names></name>
<name><surname>Akyuz</surname><given-names>M.</given-names></name>
<name><surname>Bagci</surname><given-names>N.</given-names></name>
<name><surname>Barut</surname><given-names>B.</given-names></name>
<name><surname>Unsal</surname><given-names>S.</given-names></name>
<name><surname>Sarici</surname><given-names>K.B.</given-names></name>
<etal/>
</person-group><article-title>Effect of COVID-19 Pandemic on Patients Who Have Undergone Liver Transplantation: Retrospective Cohort Study</article-title><source>J. Clin. Med.</source><year>2023</year><volume>12</volume><elocation-id>4466</elocation-id><pub-id pub-id-type="doi">10.3390/jcm12134466</pub-id><pub-id pub-id-type="pmid">37445501</pub-id>
</element-citation></ref><ref id="B2-viruses-16-01942"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azzi</surname><given-names>Y.</given-names></name>
<name><surname>Bartash</surname><given-names>R.</given-names></name>
<name><surname>Scalea</surname><given-names>J.</given-names></name>
<name><surname>Loarte-Campos</surname><given-names>P.</given-names></name>
<name><surname>Akalin</surname><given-names>E.</given-names></name>
</person-group><article-title>COVID-19 and Solid Organ Transplantation: A Review Article</article-title><source>Transplantation</source><year>2021</year><volume>105</volume><fpage>37</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1097/TP.0000000000003523</pub-id><pub-id pub-id-type="pmid">33148977</pub-id>
</element-citation></ref><ref id="B3-viruses-16-01942"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murray</surname><given-names>S.M.</given-names></name>
<name><surname>Pose</surname><given-names>E.</given-names></name>
<name><surname>Wittner</surname><given-names>M.</given-names></name>
<name><surname>Londo&#x000f1;o</surname><given-names>M.C.</given-names></name>
<name><surname>Schaub</surname><given-names>G.</given-names></name>
<name><surname>Cook</surname><given-names>J.</given-names></name>
<name><surname>Dimitriadis</surname><given-names>S.</given-names></name>
<name><surname>Meacham</surname><given-names>G.</given-names></name>
<name><surname>Irwin</surname><given-names>S.</given-names></name>
<name><surname>Lim</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients</article-title><source>J. Hepatol.</source><year>2024</year><volume>80</volume><fpage>109</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2023.10.009</pub-id><pub-id pub-id-type="pmid">37863203</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01942"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Webb</surname><given-names>G.J.</given-names></name>
<name><surname>Moon</surname><given-names>A.M.</given-names></name>
<name><surname>Barnes</surname><given-names>E.</given-names></name>
<name><surname>Barritt</surname><given-names>A.S.t.</given-names></name>
<name><surname>Marjot</surname><given-names>T.</given-names></name>
</person-group><article-title>Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients</article-title><source>J. Hepatol.</source><year>2021</year><volume>75</volume><fpage>226</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.01.036</pub-id><pub-id pub-id-type="pmid">33556419</pub-id>
</element-citation></ref><ref id="B5-viruses-16-01942"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burra</surname><given-names>P.</given-names></name>
<name><surname>Russo</surname><given-names>F.P.</given-names></name>
</person-group><article-title>Sars-Cov-2 vaccination in liver transplant recipients: The &#x02018;holy grail&#x02019; in a hostile environment</article-title><source>Liver Int.</source><year>2022</year><volume>42</volume><fpage>1225</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1111/liv.15226</pub-id><pub-id pub-id-type="pmid">35678039</pub-id>
</element-citation></ref><ref id="B6-viruses-16-01942"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harberts</surname><given-names>A.</given-names></name>
<name><surname>Schaub</surname><given-names>G.M.</given-names></name>
<name><surname>Ruether</surname><given-names>D.F.</given-names></name>
<name><surname>Duengelhoef</surname><given-names>P.M.</given-names></name>
<name><surname>Brehm</surname><given-names>T.T.</given-names></name>
<name><surname>Karsten</surname><given-names>H.</given-names></name>
<name><surname>Fathi</surname><given-names>A.</given-names></name>
<name><surname>Jahnke-Triankowski</surname><given-names>J.</given-names></name>
<name><surname>Fischer</surname><given-names>L.</given-names></name>
<name><surname>Addo</surname><given-names>M.M.</given-names></name>
<etal/>
</person-group><article-title>Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2022</year><volume>20</volume><fpage>2558</fpage><lpage>2566.e5</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2022.06.028</pub-id><pub-id pub-id-type="pmid">35850415</pub-id>
</element-citation></ref><ref id="B7-viruses-16-01942"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Herting</surname><given-names>A.</given-names></name>
<name><surname>Jahnke-Triankowski</surname><given-names>J.</given-names></name>
<name><surname>Harberts</surname><given-names>A.</given-names></name>
<name><surname>Schaub</surname><given-names>G.M.</given-names></name>
<name><surname>L&#x000fc;tgehetmann</surname><given-names>M.</given-names></name>
<name><surname>Ruether</surname><given-names>D.F.</given-names></name>
<name><surname>Fischer</surname><given-names>L.</given-names></name>
<name><surname>Addo</surname><given-names>M.M.</given-names></name>
<name><surname>Lohse</surname><given-names>A.W.</given-names></name>
<name><surname>Schulze Zur Wiesch</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Clinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>297</elocation-id><pub-id pub-id-type="doi">10.3390/v15020297</pub-id><pub-id pub-id-type="pmid">36851510</pub-id>
</element-citation></ref><ref id="B8-viruses-16-01942"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rabinowich</surname><given-names>L.</given-names></name>
<name><surname>Grupper</surname><given-names>A.</given-names></name>
<name><surname>Baruch</surname><given-names>R.</given-names></name>
<name><surname>Ben-Yehoyada</surname><given-names>M.</given-names></name>
<name><surname>Halperin</surname><given-names>T.</given-names></name>
<name><surname>Turner</surname><given-names>D.</given-names></name>
<name><surname>Katchman</surname><given-names>E.</given-names></name>
<name><surname>Levi</surname><given-names>S.</given-names></name>
<name><surname>Houri</surname><given-names>I.</given-names></name>
<name><surname>Lubezky</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients</article-title><source>J. Hepatol.</source><year>2021</year><volume>75</volume><fpage>435</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.04.020</pub-id><pub-id pub-id-type="pmid">33892006</pub-id>
</element-citation></ref><ref id="B9-viruses-16-01942"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruether</surname><given-names>D.F.</given-names></name>
<name><surname>Schaub</surname><given-names>G.M.</given-names></name>
<name><surname>Duengelhoef</surname><given-names>P.M.</given-names></name>
<name><surname>Haag</surname><given-names>F.</given-names></name>
<name><surname>Brehm</surname><given-names>T.T.</given-names></name>
<name><surname>Fathi</surname><given-names>A.</given-names></name>
<name><surname>Wehmeyer</surname><given-names>M.</given-names></name>
<name><surname>Jahnke-Triankowski</surname><given-names>J.</given-names></name>
<name><surname>Mayer</surname><given-names>L.</given-names></name>
<name><surname>Hoffmann</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2022</year><volume>20</volume><fpage>162</fpage><lpage>172.e9</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2021.09.003</pub-id><pub-id pub-id-type="pmid">34509643</pub-id>
</element-citation></ref><ref id="B10-viruses-16-01942"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>von der Schulenburg</surname><given-names>P.</given-names></name>
<name><surname>Herting</surname><given-names>A.</given-names></name>
<name><surname>Harberts</surname><given-names>A.</given-names></name>
<name><surname>L&#x000fc;tgehetmann</surname><given-names>M.</given-names></name>
<name><surname>Jahnke-Triankowski</surname><given-names>J.</given-names></name>
<name><surname>Pischke</surname><given-names>S.</given-names></name>
<name><surname>Piecha</surname><given-names>F.</given-names></name>
<name><surname>Drolz</surname><given-names>A.</given-names></name>
<name><surname>J&#x000f6;rg</surname><given-names>V.</given-names></name>
<name><surname>H&#x000fc;bener</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>High vaccination coverage and infection rate result in a robust SARS-CoV-2-specific immunity in the majority of liver cirrhosis and transplant patients: A single-center cross-sectional study</article-title><source>United Eur. Gastroenterol. J.</source><year>2024</year><volume>12</volume><fpage>339</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1002/ueg2.12528</pub-id><pub-id pub-id-type="pmid">38279837</pub-id>
</element-citation></ref><ref id="B11-viruses-16-01942"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stankov</surname><given-names>M.V.</given-names></name>
<name><surname>Hoffmann</surname><given-names>M.</given-names></name>
<name><surname>Gutierrez Jauregui</surname><given-names>R.</given-names></name>
<name><surname>Cossmann</surname><given-names>A.</given-names></name>
<name><surname>Morillas Ramos</surname><given-names>G.</given-names></name>
<name><surname>Graalmann</surname><given-names>T.</given-names></name>
<name><surname>Winter</surname><given-names>E.J.</given-names></name>
<name><surname>Friedrichsen</surname><given-names>M.</given-names></name>
<name><surname>Ravens</surname><given-names>I.</given-names></name>
<name><surname>Ilievska</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>e1</fpage><lpage>e3</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00690-4</pub-id><pub-id pub-id-type="pmid">37995739</pub-id>
</element-citation></ref><ref id="B12-viruses-16-01942"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaku</surname><given-names>Y.</given-names></name>
<name><surname>Okumura</surname><given-names>K.</given-names></name>
<name><surname>Padilla-Blanco</surname><given-names>M.</given-names></name>
<name><surname>Kosugi</surname><given-names>Y.</given-names></name>
<name><surname>Uriu</surname><given-names>K.</given-names></name>
<name><surname>Hinay</surname><given-names>A.A.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Plianchaisuk</surname><given-names>A.</given-names></name>
<name><surname>Kobiyama</surname><given-names>K.</given-names></name>
<name><surname>Ishii</surname><given-names>K.J.</given-names></name>
<etal/>
</person-group><article-title>Virological characteristics of the SARS-CoV-2 JN.1 variant</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>e82</fpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00813-7</pub-id><pub-id pub-id-type="pmid">38184005</pub-id>
</element-citation></ref><ref id="B13-viruses-16-01942"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Jian</surname><given-names>F.</given-names></name>
<name><surname>Song</surname><given-names>W.</given-names></name>
<name><surname>Yisimayi</surname><given-names>A.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>e70</fpage><lpage>e72</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00744-2</pub-id><pub-id pub-id-type="pmid">38109919</pub-id>
</element-citation></ref><ref id="B14-viruses-16-01942"><label>14.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Buda</surname><given-names>S.</given-names></name>
<name><surname>D&#x000fc;rrwald</surname><given-names>R.</given-names></name>
<name><surname>Biere</surname><given-names>B.</given-names></name>
<name><surname>Reiche</surname><given-names>J.</given-names></name>
<name><surname>Buchholz</surname><given-names>U.</given-names></name>
<name><surname>Tolksdorf</surname><given-names>K.</given-names></name>
<name><surname>Gvaladze</surname><given-names>T.</given-names></name>
<name><surname>Schilling</surname><given-names>J.</given-names></name>
<name><surname>Lehfeld</surname><given-names>A.-S.</given-names></name>
<name><surname>Cai</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>ARE-Wochenbericht KW 47 (47. Kalenderwoche: 18.11. bis 24.11.2024)</article-title><comment>Available online: <ext-link xlink:href="https://edoc.rki.de/handle/176904/12320" ext-link-type="uri">https://edoc.rki.de/handle/176904/12320</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-17">(accessed on 17 June 2024)</date-in-citation></element-citation></ref><ref id="B15-viruses-16-01942"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Jian</surname><given-names>F.</given-names></name>
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Song</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
<name><surname>Shao</surname><given-names>F.</given-names></name>
<name><surname>Cao</surname><given-names>Y.</given-names></name>
</person-group><article-title>Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations</article-title><source>Lancet Infect. Dis.</source><year>2024</year><pub-id pub-id-type="doi">10.1016/S1473-3099(24)00738-2</pub-id><pub-id pub-id-type="pmid">39586310</pub-id>
</element-citation></ref><ref id="B16-viruses-16-01942"><label>16.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>FDA</collab>
</person-group><article-title>Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2024</article-title><comment>Available online: <ext-link xlink:href="https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2024" ext-link-type="uri">https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2024</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-17">(accessed on 17 June 2024)</date-in-citation></element-citation></ref><ref id="B17-viruses-16-01942"><label>17.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Force, EMAET</collab>
</person-group><article-title>EMA confirms its recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2024-2025</article-title><comment>Available online: <ext-link xlink:href="https://www.ema.europa.eu/en/news/etf-recommends-updating-covid-19-vaccines-target-new-jn1-variant" ext-link-type="uri">https://www.ema.europa.eu/en/news/etf-recommends-updating-covid-19-vaccines-target-new-jn1-variant</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-17">(accessed on 17 June 2024)</date-in-citation></element-citation></ref><ref id="B18-viruses-16-01942"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barros-Martins</surname><given-names>J.</given-names></name>
<name><surname>Hammerschmidt</surname><given-names>S.I.</given-names></name>
<name><surname>Cossmann</surname><given-names>A.</given-names></name>
<name><surname>Odak</surname><given-names>I.</given-names></name>
<name><surname>Stankov</surname><given-names>M.V.</given-names></name>
<name><surname>Morillas Ramos</surname><given-names>G.</given-names></name>
<name><surname>Dopfer-Jablonka</surname><given-names>A.</given-names></name>
<name><surname>Heidemann</surname><given-names>A.</given-names></name>
<name><surname>Ritter</surname><given-names>C.</given-names></name>
<name><surname>Friedrichsen</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>1525</fpage><lpage>1529</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01449-9</pub-id><pub-id pub-id-type="pmid">34262158</pub-id>
</element-citation></ref><ref id="B19-viruses-16-01942"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kleine-Weber</surname><given-names>H.</given-names></name>
<name><surname>Elzayat</surname><given-names>M.T.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Graham</surname><given-names>B.S.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>M.A.</given-names></name>
<name><surname>Drosten</surname><given-names>C.</given-names></name>
<name><surname>P&#x000f6;hlmann</surname><given-names>S.</given-names></name>
<name><surname>Hoffmann</surname><given-names>M.</given-names></name>
</person-group><article-title>Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization</article-title><source>J. Virol.</source><year>2019</year><volume>93</volume><fpage>e01381-18</fpage><pub-id pub-id-type="doi">10.1128/JVI.01381-18</pub-id><pub-id pub-id-type="pmid">30404801</pub-id>
</element-citation></ref><ref id="B20-viruses-16-01942"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bobrovitz</surname><given-names>N.</given-names></name>
<name><surname>Ware</surname><given-names>H.</given-names></name>
<name><surname>Ma</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Hosseini</surname><given-names>R.</given-names></name>
<name><surname>Cao</surname><given-names>C.</given-names></name>
<name><surname>Selemon</surname><given-names>A.</given-names></name>
<name><surname>Whelan</surname><given-names>M.</given-names></name>
<name><surname>Premji</surname><given-names>Z.</given-names></name>
<name><surname>Issa</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: A systematic review and meta-regression</article-title><source>Lancet Infect. Dis.</source><year>2023</year><volume>23</volume><fpage>556</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00801-5</pub-id><pub-id pub-id-type="pmid">36681084</pub-id>
</element-citation></ref><ref id="B21-viruses-16-01942"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cossmann</surname><given-names>A.</given-names></name>
<name><surname>Hoffmann</surname><given-names>M.</given-names></name>
<name><surname>Stankov</surname><given-names>M.V.</given-names></name>
<name><surname>L&#x000fc;rken</surname><given-names>K.</given-names></name>
<name><surname>Morillas Ramos</surname><given-names>G.</given-names></name>
<name><surname>Kempf</surname><given-names>A.</given-names></name>
<name><surname>Nehlmeier</surname><given-names>I.</given-names></name>
<name><surname>P&#x000f6;hlmann</surname><given-names>S.</given-names></name>
<name><surname>Behrens</surname><given-names>G.M.N.</given-names></name>
<name><surname>Dopfer-Jablonka</surname><given-names>A.</given-names></name>
</person-group><article-title>Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>e145</fpage><lpage>e146</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00783-1</pub-id><pub-id pub-id-type="pmid">38211602</pub-id>
</element-citation></ref><ref id="B22-viruses-16-01942"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Favresse</surname><given-names>J.</given-names></name>
<name><surname>Gillot</surname><given-names>C.</given-names></name>
<name><surname>Cabo</surname><given-names>J.</given-names></name>
<name><surname>David</surname><given-names>C.</given-names></name>
<name><surname>Dogn&#x000e9;</surname><given-names>J.M.</given-names></name>
<name><surname>Douxfils</surname><given-names>J.</given-names></name>
</person-group><article-title>Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster</article-title><source>Int. J. Infect. Dis.</source><year>2024</year><volume>143</volume><fpage>107028</fpage><pub-id pub-id-type="doi">10.1016/j.ijid.2024.107028</pub-id><pub-id pub-id-type="pmid">38583825</pub-id>
</element-citation></ref><ref id="B23-viruses-16-01942"><label>23.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Buda</surname><given-names>S.</given-names></name>
<name><surname>D&#x000fc;rrwald</surname><given-names>R.</given-names></name>
<name><surname>Biere</surname><given-names>B.</given-names></name>
<name><surname>Reiche</surname><given-names>J.</given-names></name>
<name><surname>Buchholz</surname><given-names>U.</given-names></name>
<name><surname>Tolksdorf</surname><given-names>K.</given-names></name>
<name><surname>Gvaladze</surname><given-names>T.</given-names></name>
<name><surname>Schilling</surname><given-names>J.</given-names></name>
<name><surname>Goerlitz</surname><given-names>L.</given-names></name>
<name><surname>Streib</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>ARE-Wochenbericht KW3 (3. Kalenderwoche: 15.1. bis 21.1.2024)</article-title><comment>Available online: <ext-link xlink:href="https://edoc.rki.de/handle/176904/11464" ext-link-type="uri">https://edoc.rki.de/handle/176904/11464</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-17">(accessed on 17 June 2024)</date-in-citation></element-citation></ref><ref id="B24-viruses-16-01942"><label>24.</label><element-citation publication-type="webpage"><article-title>Variants Dashboard</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://public.data.rki.de/t/public/views/IGS_Dashboard/DashboardVariants?%3Aembed=y&#x00026;%3AisGuestRedirectFromVizportal=y" ext-link-type="uri">https://public.data.rki.de/t/public/views/IGS_Dashboard/DashboardVariants?%3Aembed=y&#x00026;%3AisGuestRedirectFromVizportal=y</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-08-06">(accessed on 6 August 2024)</date-in-citation></element-citation></ref><ref id="B25-viruses-16-01942"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adiprasito</surname><given-names>J.B.</given-names></name>
<name><surname>Nowacki</surname><given-names>T.</given-names></name>
<name><surname>Vollenberg</surname><given-names>R.</given-names></name>
<name><surname>Meier</surname><given-names>J.A.</given-names></name>
<name><surname>Rennebaum</surname><given-names>F.</given-names></name>
<name><surname>Schomacher</surname><given-names>T.</given-names></name>
<name><surname>Trebicka</surname><given-names>J.</given-names></name>
<name><surname>Fischer</surname><given-names>J.</given-names></name>
<name><surname>Lorentzen</surname><given-names>E.U.</given-names></name>
<name><surname>Tepasse</surname><given-names>P.R.</given-names></name>
</person-group><article-title>SARS-CoV-2 Infection Enhances Humoral Immune Response in Vaccinated Liver Transplant Recipients</article-title><source>Antibodies</source><year>2024</year><volume>13</volume><elocation-id>78</elocation-id><pub-id pub-id-type="doi">10.3390/antib13030078</pub-id><pub-id pub-id-type="pmid">39329897</pub-id>
</element-citation></ref><ref id="B26-viruses-16-01942"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peled</surname><given-names>Y.</given-names></name>
<name><surname>Afek</surname><given-names>A.</given-names></name>
<name><surname>Patel</surname><given-names>J.K.</given-names></name>
<name><surname>Raanani</surname><given-names>E.</given-names></name>
<name><surname>Segev</surname><given-names>A.</given-names></name>
<name><surname>Ram</surname><given-names>E.</given-names></name>
<name><surname>Fardman</surname><given-names>A.</given-names></name>
<name><surname>Beigel</surname><given-names>R.</given-names></name>
<name><surname>Jurkowicz</surname><given-names>M.</given-names></name>
<name><surname>Atari</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Sixth monovalent XBB.1.5 vaccine elicits robust immune response against emerging SARS-CoV-2 variants in heart transplant recipients</article-title><source>J. Heart Lung Transplant.</source><year>2024</year><volume>43</volume><fpage>1188</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1016/j.healun.2024.03.014</pub-id><pub-id pub-id-type="pmid">38522765</pub-id>
</element-citation></ref><ref id="B27-viruses-16-01942"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johnston</surname><given-names>T.S.</given-names></name>
<name><surname>Hage</surname><given-names>C.</given-names></name>
<name><surname>Abedon</surname><given-names>A.T.</given-names></name>
<name><surname>Panda</surname><given-names>S.</given-names></name>
<name><surname>Alejo</surname><given-names>J.L.</given-names></name>
<name><surname>Eby</surname><given-names>Y.</given-names></name>
<name><surname>Segev</surname><given-names>D.L.</given-names></name>
<name><surname>Tobian</surname><given-names>A.A.R.</given-names></name>
<name><surname>Cox</surname><given-names>A.L.</given-names></name>
<name><surname>Werbel</surname><given-names>W.A.</given-names></name>
<etal/>
</person-group><article-title>Rapid Wane and Recovery of XBB Sublineage Neutralization After Sequential Omicron-based Vaccination in Solid Organ Transplant Recipients</article-title><source>Clin. Infect. Dis.</source><year>2024</year><volume>79</volume><fpage>652</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1093/cid/ciae279</pub-id><pub-id pub-id-type="pmid">38953683</pub-id>
</element-citation></ref><ref id="B28-viruses-16-01942"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lustig</surname><given-names>Y.</given-names></name>
<name><surname>Barda</surname><given-names>N.</given-names></name>
<name><surname>Weiss-Ottolenghi</surname><given-names>Y.</given-names></name>
<name><surname>Indenbaum</surname><given-names>V.</given-names></name>
<name><surname>Margalit</surname><given-names>I.</given-names></name>
<name><surname>Asraf</surname><given-names>K.</given-names></name>
<name><surname>Doolman</surname><given-names>R.</given-names></name>
<name><surname>Chalkias</surname><given-names>S.</given-names></name>
<name><surname>Das</surname><given-names>R.</given-names></name>
<name><surname>Elfatarany</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><fpage>126010</fpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.05.058</pub-id><pub-id pub-id-type="pmid">38806352</pub-id>
</element-citation></ref><ref id="B29-viruses-16-01942"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arora</surname><given-names>P.</given-names></name>
<name><surname>Happle</surname><given-names>C.</given-names></name>
<name><surname>Kempf</surname><given-names>A.</given-names></name>
<name><surname>Nehlmeier</surname><given-names>I.</given-names></name>
<name><surname>Stankov</surname><given-names>M.V.</given-names></name>
<name><surname>Dopfer-Jablonka</surname><given-names>A.</given-names></name>
<name><surname>Behrens</surname><given-names>G.M.N.</given-names></name>
<name><surname>P&#x000f6;hlmann</surname><given-names>S.</given-names></name>
<name><surname>Hoffmann</surname><given-names>M.</given-names></name>
</person-group><article-title>Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>e732</fpage><lpage>e733</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(24)00688-1</pub-id><pub-id pub-id-type="pmid">39522531</pub-id>
</element-citation></ref><ref id="B30-viruses-16-01942"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Happle</surname><given-names>C.</given-names></name>
<name><surname>Hoffmann</surname><given-names>M.</given-names></name>
<name><surname>Kempf</surname><given-names>A.</given-names></name>
<name><surname>Nehlmeier</surname><given-names>I.</given-names></name>
<name><surname>Stankov</surname><given-names>M.V.</given-names></name>
<name><surname>Calderon Hampel</surname><given-names>N.</given-names></name>
<name><surname>Witte</surname><given-names>T.</given-names></name>
<name><surname>P&#x000f6;hlmann</surname><given-names>S.</given-names></name>
<name><surname>Behrens</surname><given-names>G.M.N.</given-names></name>
<name><surname>Dopfer-Jablonka</surname><given-names>A.</given-names></name>
</person-group><article-title>Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>e674</fpage><lpage>e676</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(24)00603-0</pub-id><pub-id pub-id-type="pmid">39341219</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-16-01942-f001"><label>Figure 1</label><caption><p>(<bold>A</bold>,<bold>B</bold>) Concentrations of Wuhan-Hu-1 S-specific IgG and Omicron S-specific IgG in plasma of all LTRs (<italic toggle="yes">n</italic> = 34) taken before and after vaccination with BNT162b2 Omicron XBB.1.5 vaccine or after vaccination and infection. (<bold>C</bold>,<bold>D</bold>) Concentrations of Wuhan-Hu-1 S-specific IgG and Omicron S-specific IgG in plasma in all LTRs with sole vaccination taken before and after vaccination with BNT162b2 Omicron XBB.1.5 vaccine (<italic toggle="yes">n</italic> = 28). (<bold>E</bold>,<bold>F</bold>) Concentrations of Wuhan-Hu-1 S-specific IgG and Omicron S-specific IgG in plasma in LTRs with breakthrough infection shortly after vaccination taken before vaccination with BNT162b2 Omicron XBB.1.5 vaccine and after vaccination and infection (<italic toggle="yes">n</italic> = 6). Paired T-test performed statistical significance (*** = <italic toggle="yes">p</italic> &#x0003c; 0.001). Red dots represent individual LTRs, grey lines connect paired data points for the same LTR. Abbreviations: IgG: immunoglobulin G; Vac: vaccination; S: spike.</p></caption><graphic xlink:href="viruses-16-01942-g001" position="float"/></fig><fig position="float" id="viruses-16-01942-f002"><label>Figure 2</label><caption><p>(<bold>A</bold>&#x02013;<bold>C</bold>) Analysis of neutralization capacity of antibodies before and after XBB.1.5 vaccination or vaccination and infection against B.1, XBB.1.5, and JN.1 in LTRs. Wilcoxon signed-rank test assessed statistical significance (ns = <italic toggle="yes">p &#x0003e; 0.05;</italic> ** = <italic toggle="yes">p</italic> &#x0003c; 0.01; *** = <italic toggle="yes">p</italic> &#x0003c; 0.001). For graphical reasons, plasma samples below the limit of detection were set at bottom of axis. Grey dots, green squares, and purple triangles represent the individual responses of LTRs to B.1, XBB.1.5, and JN.1, respectively. Columns indicate the geometric mean NT50 values. Abbreviations: LTRs: liver transplant recipients; GMT: geometric mean titer; Recipr: reciprocal.</p></caption><graphic xlink:href="viruses-16-01942-g002" position="float"/></fig><fig position="float" id="viruses-16-01942-f003"><label>Figure 3</label><caption><p>Scattergram with individual interferon-gamma (IFN- &#x003b3;) levels before and after XBB.1.5 vaccination. The Mann&#x02013;Whitney Test performed statistical analysis (* = <italic toggle="yes">p</italic> &#x0003c; 0.05). The blue circles represent IFN- &#x003b3; levels in individual LTRs. Solid lines represent median and interquartile range. Dotted lines represent cut-off values with interferon-gamma (IFN-&#x003b3;) levels of &#x0003c;100 mlU/mL being negative, 100&#x02013;200 mlU/mL being low positive, and &#x0003e;200 mlU/mL being high-positive. Abbreviations: LTRs: liver transplant recipients; IFN- &#x003b3;: interferon-gamma; Vac: vaccination.</p></caption><graphic xlink:href="viruses-16-01942-g003" position="float"/></fig><table-wrap position="float" id="viruses-16-01942-t001"><object-id pub-id-type="pii">viruses-16-01942-t001_Table 1</object-id><label>Table 1</label><caption><p>Baseline Characteristics of all study participants. Frequencies and percentages are given for nominal and ordinal variables. For numerical variables median and range were calculated.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">All LTRs at Baseline<break/><italic toggle="yes">n</italic> = 34<break/><italic toggle="yes">n</italic> (%)/Median (Range)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age (years)</td><td align="center" valign="middle" rowspan="1" colspan="1">56 (28&#x02013;86)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Females</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (35.3%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">23.6 (17&#x02013;37)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Time since transplantation (years)</td><td align="center" valign="middle" rowspan="1" colspan="1">9.5 (0&#x02013;28)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Risk factors for severe COVID-19</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Diabetes</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (17.6%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Arterial hypertension</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (58.8%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age &#x0003e; 60 years</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (44.1%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">eGFR &#x0003c; 45 mL/min</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (41.1%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BMI &#x0003e; 30 kg/m<sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6 (17.6%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2 risk factors</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (29.4%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265;3 risk factors</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (23.5%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Charlson comorbidity index</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (1&#x02013;9)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vaccination status at baseline</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2 doses</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (5.9%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3 doses</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (14.7%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4 doses</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (50%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5 doses</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (29.4%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Median number of prior vaccine doses</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (2&#x02013;5)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Prior Infections</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Previously infected</td><td align="center" valign="middle" rowspan="1" colspan="1">31 (91.2%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;1 prior infection</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (8.8%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Immunosuppression</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Monotherapy</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.9%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2 Immunosuppressants</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (52.9%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;3 Immunosuppressants</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 (44.1%)</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: LTRs: liver transplant recipients; BMI: body mass index; eGFR: estimated glomerular filtration rate.</p></fn></table-wrap-foot></table-wrap></floats-group></article>